Literature DB >> 16807643

A common origin of the 4143insA ADAMTS13 mutation.

Reinhard Schneppenheim1, Johanna A Kremer Hovinga, Tim Becker, Ulrich Budde, Diana Karpman, Wolfgang Brockhaus, Ingrid Hrachovinová, Bartosz Korczowski, Florian Oyen, Simon Rittich, Johannes von Rosen, Geir E Tjønnfjord, John E Pimanda, Thomas F Wienker, Bernhard Lämmle.   

Abstract

Severely deficient activity of the von Willebrand Factor (VWF) cleaving metalloprotease, ADAMTS13, is associated with thrombotic thrombocytopenic purpura (TTP). The mutation spectrum ofADAMTS13 is rather heterogeneous, and numerous mutations spread across the gene have been described in association with congenital TTP. The 4143insA mutation is unusual with respect to its geographic concentration. Following the initial report from Germany in which the 4143insA mutation was detected in four apparently unrelated families, we have now identified this mutation in a further eleven patients from Norway, Sweden, Poland, Germany, the Czech Republic and Australia. Confirmation that the Australian patient is of German ancestry, together with the Northern and Central European origin of most of the other patients, suggests that the 4143insA mutation has a common genetic background. We established ADAMTS13 haplotypes by analyzing 17 polymorphic intragenic markers. The haplotypes linked to 4143insA were identical in all informative families. Three novel candidate mutations, C347S, P671L and R1060W, as well as the known mutation R507Q, were also identified during the course of the study. We conclude that 4143insA has a common genetic background and is frequent among patients with hereditary ADAMTS13 deficiency in Northern and Central European countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16807643     DOI: 10.1160/TH05-12-0817

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  12 in total

Review 1.  ADAMTS13 and microvascular thrombosis.

Authors:  Han-Mou Tsai
Journal:  Expert Rev Cardiovasc Ther       Date:  2006-11

Review 2.  Inherited thrombotic thrombocytopenic purpura.

Authors:  Miriam Galbusera; Marina Noris; Giuseppe Remuzzi
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

Review 3.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

4.  Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Johan Rebetz; Li Wang; Christoph Licht; David Motto; Diana Karpman
Journal:  J Immunol       Date:  2013-07-22       Impact factor: 5.422

Review 5.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

6.  The first deletion mutation in the TSP1-6 repeat domain of ADAMTS13 in a family with inherited thrombotic thrombocytopenic purpura.

Authors:  Roberta Palla; Silvia Lavoretano; Rossana Lombardi; Isabella Garagiola; Mehran Karimi; Abdolreza Afrasiabi; Mani Ramzi; Raimondo De Cristofaro; Flora Peyvandi
Journal:  Haematologica       Date:  2008-12-30       Impact factor: 9.941

7.  Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.

Authors:  Xinping Fan; Johanna A Kremer Hovinga; Hiroko Shirotani-Ikejima; Yuka Eura; Hidenori Hirai; Shigenori Honda; Koichi Kokame; Magnus Mansouri Taleghani; Anne-Sophie von Krogh; Yoko Yoshida; Yoshihiro Fujimura; Bernhard Lämmle; Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2016-02-01       Impact factor: 2.490

8.  ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; AnnCharlotte Kristoffersson; Han-Mou Tsai; Wenhua Zhou; Ingemar Winqvist; Göran Oldaeus; Rolf Billström; Peter Björk; Lars Holmberg; Diana Karpman
Journal:  Eur J Pediatr       Date:  2006-12-24       Impact factor: 3.183

9.  Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation.

Authors:  Anton Letzer; Katja Lehmann; Christian Mess; Gesa König; Tobias Obser; Sven Peine; Sonja Schneppenheim; Ulrich Budde; Stefan W Schneider; Reinhard Schneppenheim; Maria A Brehm
Journal:  PLoS One       Date:  2020-05-04       Impact factor: 3.240

Review 10.  Proteolytic processing of von Willebrand factor by adamts13 and leukocyte proteases.

Authors:  Stefano Lancellotti; Maria Basso; Raimondo De Cristofaro
Journal:  Mediterr J Hematol Infect Dis       Date:  2013-09-02       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.